SEC Form 4 · accession 0001567619-18-002982
KalVista Pharmaceuticals, Inc. · KALV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Benjamin L Palleiko
Officer — CFO and Secretary
Period of report
Sep 18, 2018
Accepted (ET)
Sep 20, 2018 · 7:29 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001348911
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Sep 18, 2018 | A | 32,500 | $0.00 | A | 32,500 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F2 | $16.08 | Sep 18, 2018 | A | 52,600 | A | — | Sep 17, 2028 | Common Stock | 52,600 | 52,600 | D |
Explanation of responses
- F1Represents the number of shares vested upon the achievement of certain performance criteria pursuant to a performance based restricted stock unit granted by the Issuer's Compensation Committee in June 2018. No sale or disposition of these shares is contemplated until after the expiration of the applicable lock-up period.
- F2The option vests over a 4 year period: 1/48th on October 18, 2018, after which 1/48th of the total shares vest monthly, subject to continued service through each vesting date.